BIOCHEMICAL TOPICAL GROUP
The Biochemical Topical Group collaborates with the Biochemical Pharmacology Discussion Group of The New York Academy of Sciences to sponsor 8 symposia per year.
The topics and speakers are selected from Proposals submitted to the Steering Committee, which met on March 24th to discuss them. The 24 Proposals are attached. All scientists are invited to vote on the Proposals.
The 8 receiving the most votes constitutes the next year's Program. The scientist who suggests the topic then chairs that meeting.
The symposia are held at The New York Academy of Sciences, 7 World Trade Center, and include 4-6 speakers, usually from 1:00 - 5:00 pm.
A coffee break in the middle enables interactions. Two symposia may be full-day.
We represent a diverse group of scientists with an interest in biochemistry, molecular biology, biomedical research, and related areas.
Members are from pharmaceutical and biotechnology companies, and university and medical center research facilities across the Eastern United States.
Our purpose is to bring together diverse institutions and communities, industrial and academic, to share new and relevant information at the frontiers of research and development.
For further info please contact:
Dr. Barbara Petrack Chair, Biochemical Topical Group
Drew University
Dept. RISE
36 Madison Ave
Madison, NJ 07940
Tel: 973-408-3567
FAX: 973-408-3504
Email
Meetings/Symposia
Fall 2009 Events
October 27, 2009
Emerging Importance of Companion Diagnostics in Drug Development
A Symposium Organized by Carol Reed, Clinical Data, Inc. and George Zavoico, Westport Capital Markets, LLC
1:00 pm - 5:00 pm
Molecular diagnostics is a rapidly growing field in the management of many diseases. Technological advancements, understanding
of disease pathophysiology, and emergence of personalized medicine are putting new demands on drug development.
This symposium will bring together some of the elements highlighting the demands, challenges, and successes in this exciting new era of disease management.
Location: The New York Academy of Sciences Conference Center
7 World Trade Center, 250 Greenwich Street - 40th Floor, New York, NY
Directions
Reservations
October 27, 2009
Is Alzheimer's Disease Type 3 Diabetes ???
A Symposium Organized by Barbara Petrack, Drew University, and Jean Lachowitz, Schering-Plough Research Institute
1:00 pm - 5:00 pm
Program
The two hallmarks of Alzheimer's Disease (AD) are amyloid plaque deposition and hyperphosphorylated tau-mediated tangle formation.
While inhibitors of these processes are now being studied in the clinic, currently available therapies such as cholinesterase inhibitors and the
NMDA antagonist memantine only treat symptoms of AD. A less-studied aspect of AD etiology involves insulin dysregulation in the brain.
Recent studies of postmortem brains from AD patients suggest that sporadic AD may result from a cascade involving dysregulated neuronal
insulin signaling systems. This cascade is associated with generation of reactive oxygen and nitrogen species, mitochondrial
dysfunction and cholinergic neuronal degeneration, in addition to plaque and tangle formation. Whether AD is Type 3 diabetes,
unique to the brain, or whether diabetes is a risk factor for AD remains to be elucidated. Understanding the connection between
insulin function and AD might enable discovery of a drug-combination that prevents, delays, or halts progression of sporadic AD.
Location: The New York Academy of Sciences Conference Center
7 World Trade Center, 250 Greenwich Street - 40th Floor, New York, NY
Directions
Reservations
See the current issue of
The Indicator
for meeting information
American Chemical Society
New York Section, Inc.
Department of Chemistry
St. John's University
8000 Utopia Parkway
Jamaica, NY 11439
Phone 516-883-7510
Fax 516-883-4003
E-Mail Inquiries to our Office Administrator
